Full Press Release Details
Tiziana Life Sciences Announces Appointment of Mr. Gregor MacRae to strengthen the Board
21 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development
of innovative therapeutics for inflammation and oncology indications, is pleased to announce appointment of Mr. Gregor MacRae to
its Board as a Non-executive Director.
Mr. Gregor MacRae holds a Law degree
(LLB Hons) from the University of Birmingham. He is a qualified Chartered Accountant (ICAEW) and has been a financial and business
strategy adviser to multiple companies. Presently, Gregor is the Senior Partner of Appledore Wealth Management LLP, a London-based
high net worth business advisory partnership. Gregor also served as a director of Chiltern Group Plc, an international trust company.
"I am delighted to join the Board of
Tiziana and I am looking forward to working with the Company. I believe my experience as an advisor to several international companies
over the last 25 years will compliment Tiziana and I am more than happy to join the Company at this exciting time", said
"We are delighted to have Gregor
join our team as he brings rich experience to help and advise companies in their financial and business strategies. His appointment
is a step towards reshaping the Board ahead of the Company's intention to become a solely NASDAQ listed company" said
Dr. Shailubhai, CEO & CSO of Tiziana Life Sciences.
Tiziana Life Sciences previously announced
that it has appointed advisers in relation to an intended redomicile of the Company to Bermuda, to delist the Company's ordinary
shares from its AIM listing and to cancel its ADR program in order to facilitate listing of its Bermuda common shares on NASDAQ.
As a result, Tiziana Life Sciences will only be listed on NASDAQ and all current ADRs and AIM shares will be replaced by NASDAQ
In 2019 Tiziana announced the successful
completion of three clinical studies, a phase 2a clinical trial with milciclib in sorafenib-resistant hepatocellular carcinoma,
a phase 1 study with nasal administration of Foralumab, a fully human anti-CD3 monoclonal antibody, and a phase 1 clinical trial
with oral administration of Foralumab.
Pursuant to Rule 17 and Schedule 2(g) of
the AIM Rules for Companies, the following information is disclosed in respect of Gregor Charles William MacRae (aged 57):
| Current Appointments | Appointments in the last five years | |
| OKYO Pharma Limited | Elysium Golf Limited | |
| Appledore Sports Management Limited | Opskic Group Limited | |
| Appledore Property Management Limited | Amorim Partners Limited | |
| Appledore Bleu des Mers Limited | Sorino Limited | |
| Appledore Consulting Limited | Sorino (UK) Limited | |
| Appledore Wealth Management LLP | Sidero Limited | |
| B C Estates Limited | Mayze Services Limited | |
| Clarges Consultancy Limited | Pretzi Limited | |
| Hampton Resources Limited | ||
| Semolin Limited | ||
| Triple 8 Holdings Limited | ||
| Pinta Consultancy Limited | ||
| Crazele Properties Limited |
There is no further information to be disclosed
in relation to the appointments of Mr MacRae pursuant to AIM Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.
This announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib,
the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in
clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory
diseases, such as nonalcoholic steatohepatitis ("NASH"), ulcerative colitis, multiple sclerosis, type-1 diabetes ("T1D"),
Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,'
intends,' plans,' believes,' seeks,' estimates,' and similar expressions
are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult
to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements,
which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement
relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release
publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events
occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
| Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 | |
| Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner | + 44 (0)20 7213 0880 | |
| Shore Capital (Broker) Antonio Bossi / Fiona Conroy | +44 (0)20 7601 6125 |
Receive news and updates from Tiziana Life
Sciences plc by signing up to get email alerts straight to you on https://ir.tizianalifesciences